SG11201604512XA - Reduction of inflammatory disease symptoms by short peptides that inhibit signaling through cd28 - Google Patents

Reduction of inflammatory disease symptoms by short peptides that inhibit signaling through cd28

Info

Publication number
SG11201604512XA
SG11201604512XA SG11201604512XA SG11201604512XA SG11201604512XA SG 11201604512X A SG11201604512X A SG 11201604512XA SG 11201604512X A SG11201604512X A SG 11201604512XA SG 11201604512X A SG11201604512X A SG 11201604512XA SG 11201604512X A SG11201604512X A SG 11201604512XA
Authority
SG
Singapore
Prior art keywords
reduction
inflammatory disease
disease symptoms
short peptides
inhibit signaling
Prior art date
Application number
SG11201604512XA
Other languages
English (en)
Inventor
Raymond Kaempfer
Anat Shirvan
Gila Arad
Original Assignee
Yissum Res Dev Co
Atox Bio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Res Dev Co, Atox Bio Ltd filed Critical Yissum Res Dev Co
Publication of SG11201604512XA publication Critical patent/SG11201604512XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
SG11201604512XA 2013-12-06 2014-12-07 Reduction of inflammatory disease symptoms by short peptides that inhibit signaling through cd28 SG11201604512XA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361912631P 2013-12-06 2013-12-06
US201461924869P 2014-01-08 2014-01-08
PCT/IL2014/051067 WO2015083173A1 (en) 2013-12-06 2014-12-07 Reduction of inflammatory disease symptoms by short peptides that inhibit signaling through cd28

Publications (1)

Publication Number Publication Date
SG11201604512XA true SG11201604512XA (en) 2016-07-28

Family

ID=52396781

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201604512XA SG11201604512XA (en) 2013-12-06 2014-12-07 Reduction of inflammatory disease symptoms by short peptides that inhibit signaling through cd28
SG10201804750XA SG10201804750XA (en) 2013-12-06 2014-12-07 Reduction of inflammatory disease symptoms by short peptides that inhibit signaling through cd28

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201804750XA SG10201804750XA (en) 2013-12-06 2014-12-07 Reduction of inflammatory disease symptoms by short peptides that inhibit signaling through cd28

Country Status (7)

Country Link
US (2) US9963497B2 (ja)
EP (1) EP3077415B1 (ja)
JP (1) JP6757667B2 (ja)
AU (2) AU2014358677A1 (ja)
CA (1) CA2932150A1 (ja)
SG (2) SG11201604512XA (ja)
WO (1) WO2015083173A1 (ja)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2932150A1 (en) * 2013-12-06 2015-06-11 Atox Bio Ltd. Reduction of inflammatory disease symptoms by short peptides that inhibit signaling through cd28
US11344578B2 (en) 2017-04-19 2022-05-31 Board Of Regents, The University Of Texas System Immune cells expressing engineered antigen receptors
EP3691672A1 (en) 2017-10-06 2020-08-12 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd Peptides for use in the treatment of viral infections
CN111253469B (zh) * 2020-03-06 2021-09-07 暨南大学 一种自组装短肽及其在治疗痤疮方面的应用
WO2023080790A1 (en) * 2021-11-02 2023-05-11 Tosoj As Tri-, tetra and pentapeptides, compositions thereof and their use in the therapy of psoriasis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004087754A1 (en) 2003-04-03 2004-10-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Broad-spectrum in-vivo effective superantigen toxin antagonists based on the interaction between cd28 and the superantigen and uses thereof
US8535672B2 (en) * 2002-04-04 2013-09-17 Yissum Research Development Of The Hebrew University Of Jerusalem Broad-spectrum in-vivo effective superantigen toxin antagonists based on the interaction between CD28 and the superantigen and uses thereof
US20110097339A1 (en) * 2008-07-18 2011-04-28 Domantis Limited Compositions monovalent for CD28 binding and methods of use
WO2011101791A1 (en) * 2010-02-18 2011-08-25 Tcl Pharma Anti-cd28 humanized antibodies
DE102012008730A1 (de) 2011-12-02 2013-06-06 Dr. Budz GmbH Orale Zusammensetzungen mit ungesättigten C18-Fettsäuren und ihre Verwendung
CA2860460A1 (en) 2012-01-16 2013-07-25 Atox Bio Ltd. Use of synthetic p2ta peptides in the treatment of ongoing bacterial infection and associated inflammation
CA2932150A1 (en) * 2013-12-06 2015-06-11 Atox Bio Ltd. Reduction of inflammatory disease symptoms by short peptides that inhibit signaling through cd28

Also Published As

Publication number Publication date
JP2017501999A (ja) 2017-01-19
US10280209B2 (en) 2019-05-07
SG10201804750XA (en) 2018-07-30
AU2017261479B2 (en) 2019-05-02
US20180215804A1 (en) 2018-08-02
EP3077415A1 (en) 2016-10-12
JP6757667B2 (ja) 2020-09-23
CA2932150A1 (en) 2015-06-11
US20160289295A1 (en) 2016-10-06
EP3077415B1 (en) 2020-02-12
AU2014358677A1 (en) 2016-06-02
AU2017261479A1 (en) 2017-11-30
US9963497B2 (en) 2018-05-08
WO2015083173A1 (en) 2015-06-11

Similar Documents

Publication Publication Date Title
IL243445B (en) Silencer
HK1223340A1 (zh) 材料處理系統
GB2515794B (en) Improvements Relating to Vehicles
EP2816578A4 (en) COMMERCIAL VEHICLE
GB201309667D0 (en) Improvements to social alarms
SG11201604512XA (en) Reduction of inflammatory disease symptoms by short peptides that inhibit signaling through cd28
FR3001437B1 (fr) Systeme de reduction/augmentation progressive de voilure rigide
GB201318039D0 (en) Engine system
EP2929915A4 (en) CULTURISM DEVICE
HK1216994A1 (zh) 減少自身免疫性疾病的風險
GB201316866D0 (en) Two-stage turbocharger system
GB2522110B (en) System integration
GB201319445D0 (en) Self-assembly of nanotubes
ZA201600071B (en) Pyridine-2-carboxamides as nematocides
GB201308020D0 (en) Vehicle composite structure
HUE037998T2 (hu) Öregíthetõ acél
PL2956136T3 (pl) D-fagomina do zapobiegania wystąpienia chorób autoimmunologicznych
EP2970869A4 (en) REPRESSIBLE PROMOTER WITH LOW PHOSPHATE CONTENT
EP2974517A4 (en) MOTIVATION-INTRODUCED TELECONFERENCE
GB201314581D0 (en) Purification
GB201304194D0 (en) Use of cladribine for treating autoimmune inflammatory disease
IL241331B (en) Delay of degenerative diseases
IL239572A0 (en) Multifocal lenses
AU2013236V (en) CR001 Correa alba
GB201300231D0 (en) Car Viz